WASHINGTON--(BUSINESS WIRE)--The Association of Clinical Research Organizations (ACRO) is pleased to announce that its written comments to regulatory public consultations in both the U.S. and EU are now available on its website.
As a key stakeholder in drug development and clinical research, ACRO submits written comments to regulatory public consultations in the U.S., Europe, and worldwide. ACRO provides input to a range of agencies – including the Food and Drug Administration, the National Institutes of Health, the European Medicines Agency, and the European Commission. The library contains approximately 50 written comments from the last few years and will be updated on a regular basis.
Karen Noonan, ACRO Vice President of Global Regulatory Policy stated: “ACRO’s comment letters to regulatory and legislative public consultations are an important component of our larger advocacy program. In addition to in-person meetings with regulators and robust participation in multi-stakeholder regulatory workshops and advisory committees, these comment letters provide an opportunity for the expertise and hands-on insights of the global CRO industry to help inform and positively influence developing regulations and guidelines.”
ACRO hopes this easily accessible, web-based central repository of comments will be helpful to stakeholders across the entire drug development ecosystem – including ACRO members, other industry associations, policymakers, and patient organizations.
About ACRO
The Association of Clinical Research Organizations (ACRO) represents companies that provide a variety of specialized services that support the development of new pharmaceuticals, biologics, and medical devices. Through its member companies, ACRO helps improve the quality, efficiency and safety of biomedical research. ACRO member companies employ more than 130,000 professionals worldwide and conduct research in more than 100 countries. For more information, please visit www.acrohealth.org. Twitter @acrohealth. YouTube @ACROHealthChannel. Facebook. LinkedIn.
